Literature DB >> 32793708

Methylation of the MAOA promoter is associated with schizophrenia.

Hao Yang1,2, Jiajue Li1,2, Aicen Ji1,2, Liping Hu2, Xiufeng Zhang2, Linlin Liu2, Lili Qing1,2, Ming Yan1,2, Shengjie Nie2.   

Abstract

BACKGROUND: Earlier studies have shown that patients with schizophrenia have abnormalities in DNA methylation. Monoamine oxidase A (MAOA) has been extensively studied due to its biological role in neurological function. However, the relationship between the DNA methylation of the MAOA gene and schizophrenia is unclear. This study aims to elucidate the relationship between the methylation of the MAOA gene promoter and schizophrenia.
METHODS: There were 151 individuals with schizophrenia (104 males and 47 females), which were diagnosed according to DSM-V, the DNA of peripheral blood of all samples was extracted and chemically modified with bisulfite. The promoter region of MAOA gene was sequenced by Methylation Target Technical Method (MethylTargetTM), and 247 controls (204 males and 43 females) included in the study. MAOA gene promoter methylation was compared between the case and control groups. Meanwhile, we measured DNA methylation in two regions of MAOA (MAOA-2 and MAOA-3).
RESULTS: In the male schizophrenia group (BM) and the male control group (DM), MAOA-2 and MAOA-3 methylation were positively associated with schizophrenia. In the female schizophrenia group (BF) and the female control group (DF), MAOA-2 methylation was associated with schizophrenia.
CONCLUSIONS: Although the role of gene methylation in the development of schizophrenia is still unclear, our findings suggest that DNA methylation of MAOA may contribute to the onset of schizophrenia. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  DNA; Methylation; Monoamine oxidase A (MAOA); schizophrenia

Year:  2020        PMID: 32793708      PMCID: PMC7396778          DOI: 10.21037/atm-20-4481

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  27 in total

1.  MB-COMT promoter DNA methylation is associated with working-memory processing in schizophrenia patients and healthy controls.

Authors:  Esther Walton; Jingyu Liu; Johanna Hass; Tonya White; Markus Scholz; Veit Roessner; Randy Gollub; Vince D Calhoun; Stefan Ehrlich
Journal:  Epigenetics       Date:  2014-05-16       Impact factor: 4.528

2.  Associations Between MAOA-uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males.

Authors:  Megha Bendre; Erika Comasco; Dave Checknita; Jari Tiihonen; Sheilagh Hodgins; Kent W Nilsson
Journal:  Alcohol Clin Exp Res       Date:  2018-01-31       Impact factor: 3.455

3.  Effects of MAOA promoter methylation on susceptibility to paranoid schizophrenia.

Authors:  Yanbo Chen; Jiexu Zhang; Li Zhang; Yan Shen; Qi Xu
Journal:  Hum Genet       Date:  2011-12-24       Impact factor: 4.132

4.  The association of the HOPA(12bp) polymorphism with schizophrenia in the NIMH Genetics Initiative for Schizophrenia sample.

Authors:  Robert A Philibert; Phil Bohle; Dianna Secrest; Jessica Deaderick; Harinder Sandhu; Raymond Crowe; Donald W Black
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-09-05       Impact factor: 3.568

5.  A cis-phase interaction study of genetic variants within the MAOA gene in major depressive disorder.

Authors:  JieXu Zhang; YanBo Chen; KeRang Zhang; Hong Yang; Yan Sun; Yue Fang; Yan Shen; Qi Xu
Journal:  Biol Psychiatry       Date:  2010-08-05       Impact factor: 13.382

6.  MAOA methylation is associated with nicotine and alcohol dependence in women.

Authors:  Robert A Philibert; Tracy D Gunter; Steven R H Beach; Gene H Brody; Anup Madan
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-07-05       Impact factor: 3.568

7.  DNA methylation signatures of peripheral leukocytes in schizophrenia.

Authors:  Makoto Kinoshita; Shusuke Numata; Atsushi Tajima; Shinji Shimodera; Shinji Ono; Akira Imamura; Jun-ichi Iga; Shinya Watanabe; Kumiko Kikuchi; Hiroko Kubo; Masahito Nakataki; Satsuki Sumitani; Issei Imoto; Yuji Okazaki; Tetsuro Ohmori
Journal:  Neuromolecular Med       Date:  2012-09-09       Impact factor: 3.843

8.  Associations between DNA methylation and schizophrenia-related intermediate phenotypes - a gene set enrichment analysis.

Authors:  Johanna Hass; Esther Walton; Carrie Wright; Andreas Beyer; Markus Scholz; Jessica Turner; Jingyu Liu; Michael N Smolka; Veit Roessner; Scott R Sponheim; Randy L Gollub; Vince D Calhoun; Stefan Ehrlich
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-01-15       Impact factor: 5.067

9.  Gene-Gene-Environment Interactions of Serotonin Transporter, Monoamine Oxidase A and Childhood Maltreatment Predict Aggressive Behavior in Chinese Adolescents.

Authors:  Yun Zhang; Qing-Sen Ming; Jin-Yao Yi; Xiang Wang; Qiao-Lian Chai; Shu-Qiao Yao
Journal:  Front Behav Neurosci       Date:  2017-02-01       Impact factor: 3.558

10.  MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy.

Authors:  C Ziegler; J Richter; M Mahr; A Gajewska; M A Schiele; A Gehrmann; B Schmidt; K-P Lesch; T Lang; S Helbig-Lang; P Pauli; T Kircher; A Reif; W Rief; A N Vossbeck-Elsebusch; V Arolt; H-U Wittchen; A O Hamm; J Deckert; K Domschke
Journal:  Transl Psychiatry       Date:  2016-04-05       Impact factor: 6.222

View more
  3 in total

1.  Crossing the "Birth Border" for Epigenetic Effects.

Authors:  Debomoy K Lahiri; Bryan Maloney; Weihong Song; Deborah K Sokol
Journal:  Biol Psychiatry       Date:  2022-03-02       Impact factor: 12.810

2.  Retraction "Methylation of the MAOA promoter is associated with schizophrenia".

Authors:  Hao Yang; Jiajue Li; Aicen Ji; Liping Hu; Xiufeng Zhang; Linlin Liu; Lili Qing; Ming Yan; Shengjie Nie
Journal:  Ann Transl Med       Date:  2020-11

3.  Characteristics of global retractions of schizophrenia-related publications: A bibliometric analysis.

Authors:  Pan Chen; Xiao-Hong Li; Zhaohui Su; Yi-Lang Tang; Yi Ma; Chee H Ng; Yu-Tao Xiang
Journal:  Front Psychiatry       Date:  2022-08-01       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.